CA3219943A1 - Dry powder formulations of tacrolimus for administration by inhalation once daily (qd) - Google Patents

Dry powder formulations of tacrolimus for administration by inhalation once daily (qd) Download PDF

Info

Publication number
CA3219943A1
CA3219943A1 CA3219943A CA3219943A CA3219943A1 CA 3219943 A1 CA3219943 A1 CA 3219943A1 CA 3219943 A CA3219943 A CA 3219943A CA 3219943 A CA3219943 A CA 3219943A CA 3219943 A1 CA3219943 A1 CA 3219943A1
Authority
CA
Canada
Prior art keywords
tacrolimus
dose
composition
patient
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219943A
Other languages
English (en)
French (fr)
Inventor
Dale J. Christensen
Christopher S. Crean
John J. Koleng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TFF Pharmaceuticals Inc
Original Assignee
TFF Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TFF Pharmaceuticals Inc filed Critical TFF Pharmaceuticals Inc
Publication of CA3219943A1 publication Critical patent/CA3219943A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3219943A 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd) Pending CA3219943A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187774P 2021-05-12 2021-05-12
US63/187,774 2021-05-12
PCT/US2022/028972 WO2022241105A1 (en) 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)

Publications (1)

Publication Number Publication Date
CA3219943A1 true CA3219943A1 (en) 2022-11-17

Family

ID=81928015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219943A Pending CA3219943A1 (en) 2021-05-12 2022-05-12 Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)

Country Status (7)

Country Link
US (1) US20220362222A1 (https=)
EP (1) EP4337173A1 (https=)
JP (1) JP2024520912A (https=)
CN (1) CN117750945A (https=)
AU (1) AU2022271790A1 (https=)
CA (1) CA3219943A1 (https=)
WO (1) WO2022241105A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118948810A (zh) * 2024-07-26 2024-11-15 四川大学 一种吸入式的mPEG-PLGA/FK506载药纳米颗粒及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
AU2009214443B2 (en) 2008-02-13 2013-10-10 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
WO2011163600A2 (en) * 2010-06-25 2011-12-29 Apt Pharmaceuticals, Inc. Tacrolimus compositions for aerosol administration

Also Published As

Publication number Publication date
AU2022271790A1 (en) 2023-11-23
EP4337173A1 (en) 2024-03-20
WO2022241105A1 (en) 2022-11-17
US20220362222A1 (en) 2022-11-17
JP2024520912A (ja) 2024-05-27
CN117750945A (zh) 2024-03-22

Similar Documents

Publication Publication Date Title
US10610536B2 (en) Aerosol pirfenidone and pyridone analog compounds and uses thereof
JP2025108419A (ja) エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
US6080762A (en) Pulmonary and nasal delivery of raloxifene
JP2019519489A (ja) 肺高血圧症を治療するための乾燥粉末トレプロスチニル
AU2018206852A1 (en) Aerosol pirfenidone and pyridone analog compounds
KR20120131245A (ko) 기관지 감염의 치료 방법
JP2009510077A (ja) 抗生物質製剤、単位用量、キットおよび方法
WO2009115235A1 (en) Pde inhibitors for the treatment of pulmonary hypertension
JP2018535984A (ja) リバビリンの医薬組成物
AU2024201523A1 (en) Intranasal epinephrine formulations and methods for the treatment of disease
CN116159024A (zh) 具有弹性蛋白酶抑制活性的β-发夹肽模拟物及其气雾剂剂量形式
US20220362222A1 (en) Once daily formulations of tacrolimus
WO2024109652A1 (zh) (-)-表没食子儿茶素没食子酸酯类化合物的应用
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
KR20230005937A (ko) 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법
CN116916889A (zh) 用于肺高压领域的吸入式伊马替尼
CN114144195A (zh) 血管活性肠肽(vip)用于治疗药源性肺炎的用途
US20250352530A1 (en) Method and composition for treating lung diseases
CN113134000B (zh) 一种含松弛平滑肌的药物组合物
WO2026061535A1 (zh) 一种可吸入的含可溶性鸟苷酸环化酶受体激动剂的药物组合物及其用途以及肺动脉高压的治疗方法
KR20250002714A (ko) 폐 질환을 치료하기 위한 방법 및 조성물
KR20240124352A (ko) 흡입용 분말 및 그 제조방법
HK40121592A (en) Intranasal epinephrine formulations and methods for the treatment of disease
HK40083799A (en) Clofazimine composition and method for the treatment or prophylaxis of viral infections
CN114129546A (zh) 一种吸入用药物组合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251006

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251006

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251019